Clinical Trial

REMAP ECMO - Beta Receptor Modulation Trial

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 26, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
In this phase 2, single center, randomized clinical pilot trial, investigators will study the effect of a strategy involving a reduction of beta receptor (BR) stimulation (by decreasing dobutamine dosages) and subsequent BR inhibition (through ultra-short acting betablockers), versus a (routine) strategy with continued BR stimulation through dobutamine infusion, on heart rate in patients with cardiogenic shock due to left- or bi-ventricular failure being supported by V-A ECMO.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06522594
Lead Sponsor Erasmus Medical Center
Conditions Heart Failure, Cardiogenic Shock
Enrollment 20 participants
Start Date 2024-06-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-03 (estimated)
Updated on ClinicalTrials.gov 2024-07-26